About Ambrx
Ambrx (Nasdaq: AMAM) is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop next generation antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. Ambrx is advancing a focused portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications. Specifically, ARX517, its proprietary antibody-drug conjugates (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. Ambrx spun out of The Scripps Research Institute in 2003 and has several other product candidates involving ADCs and other aspects of Ambrx’s protein engineering technology.
Company Details
5M-10M
Biotechnology Research
51-200 employees
Public Company
San Diego, CA
United States
Frequently Asked Questions about
What is Ambrx's industry?
Ambrx operates in the Biotechnology Research industry and is headquartered in United States.
How many employees does Ambrx have?
Ambrx has approximately 51-200 employees employees.
Where is Ambrx's based?
Ambrx is based in San Diego, CA, United States.
Is Ambrx publicly listed?
Yes. Ambrx is a publicly traded company.
How can I contact Ambrx's investor relations team?
You can reach Ambrx’s investor relations department through the contact section on their official website or directly via the investor relations email listed in their latest SEC filings.
Find verified emails and phone numbers for professionals like those at
Up to 90% verified emails and mobile numbers, backed by weekly job-change alerts.
Find verified emails at this company
An email pattern tells you the format. It does not tell you who works there now or whether an address still delivers. Scalelist returns verified contacts, checked at the point you build the list.